DOI QR코드

DOI QR Code

Low Expression of the bcl2 Gene in Gastric Adenocarcinomas in Mazandaran Province of Iran

  • Mirmajidi, Seyedeh Habibeh (Department of Basic Sciences, Sari Agricultural Sciences and Natural Resources University) ;
  • Ataee, Ramin (Pharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences) ;
  • Barzegar, Ali (Department of Basic Sciences, Sari Agricultural Sciences and Natural Resources University) ;
  • Nikbakhsh, Novin (Babol University of Medical Sciences) ;
  • Shaterpour, Mohammad (Pharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences)
  • Published : 2015.09.02

Abstract

Background: Gastric cancer accounts for about 8% of the total cancer cases and 10% of total cancer deaths worldwide. It is the second lethal cancer after esophageal cancer and is considered the fourth most common cancer in north and northwest Iran. The bcl2 family has a key role in the regulation of apoptosis and change in its expression can contribute to cancer. This study initially scheduled to determine the expression of bcl2 gene in tissue samples of adenocarcinoma cancer patients. Materials and Methods: A total of 10 samples of gastric adenocarcinoma and 10 of normal tissues from Sari hospital were selected and after DNA extraction from tissues, bcl2 gene expression assayed by real-time PCR. Results: Our results demonstrated higher expression of the bcl2 gene in control compared with cancer and marginal cancer tissues. Conclusions: On one hand BCL2 plays an important role as an oncogene to inhibit apoptosis; on the other hand, it can initiate cell cycle arrest at G0 stage. Our observed association between its expression and patient survival is quite conflicting and may be tissue-specific. The data suggest expression both tumoural and non-tumoral(marginal) groups have lowered expression than controls (P>0.05). Due to the low number of samples we could not examine the relationship with clinicopathological features. However, bcl-2 expression may be important for prognostic outcome or a useful target for therapeutic intervention.

References

  1. Axon A (2006). Symptoms and diagnosis of gastric cancer at early curable stage. Best Practice & Research Clinical Gastroenterology, 20, 697-708. https://doi.org/10.1016/j.bpg.2006.03.015
  2. Antonsson B (2001). Bax and other pro-apoptotic Bcl-2 family killer- proteins and their victim, the mitochondrion. Cell Tissue Res, 306, 347-361. https://doi.org/10.1007/s00441-001-0472-0
  3. Bold RJ, Termuhlen PM< McConkey DJ (1997). Apoptosis, cancer and cancer therapy. Surgical Oncol, 6 ,133-42. https://doi.org/10.1016/S0960-7404(97)00015-7
  4. Behjati, F, Atri M, Najmabadi H, et al (2005). Prognostic value of chromosome 1 and 8 copy number in invasive ductal breast carcinoma among Iranian women. Pathol Oncol Res, 11, 157-63. https://doi.org/10.1007/BF02893392
  5. Bilim V, Tomita Y, Kawasaki T, et al (1996). Prognostic value of Bcl-2 and p53 expression in urinary tract transitional cell cancer. J Natl Cancer Inst, 88 ,686-8.
  6. Cho YG, Kim CJ, Park CH, et al (2005). Genetic alterations of the KLF6 gene in gastric cancer. Oncogene, 24, 4588-90. https://doi.org/10.1038/sj.onc.1208670
  7. Cory S, Adams JM (2002). The BCL2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer, 2, 647-56. https://doi.org/10.1038/nrc883
  8. Chipuk JE, Moldoveanu T, Llambi F, et al (2010). The Bcl-2 family reunion. Molecular Cell, 37, 299-310. https://doi.org/10.1016/j.molcel.2010.01.025
  9. Cleland MM, Norris KL, Karbowski M, et al (2010). Bcl-2 family interaction with the mitochondrial morphogenesis machinery. Cell Death Differ, 18, 235-47.
  10. Callagy GM, Webber MJ, Pharoah PD, et al (2008). Metaanalysis confirms BCL2 is an independent prognostic marker in breast cancer. Bmc Cancer, 8,153. https://doi.org/10.1186/1471-2407-8-153
  11. Favaloro B, Allocati N, Graziano V, et al (2012). Role of Apoptosis in disease. AGING Journal, 4, 5.
  12. Faderl S, Keating MJ, Do K.A ,et al (2002). Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia, 16, 1045-52. https://doi.org/10.1038/sj.leu.2402540
  13. Fontanini G, Vignati S, Bigini D, et al (1995). Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-smallcell lung cancer. Br J Cancer, 71, 1003-7. https://doi.org/10.1038/bjc.1995.193
  14. Hopkins J, Guilford P, Harraway J, et al (1998). Ecadheringermline mutations in familial gastric cancer. National Institutes of Health, 392, 402-5.
  15. Hirata H, Hinoda Y, Nakajima K, et al (2009). The BCL2-938CC Genotype Has Poor Prognosis and Lower Survival in Renal Cancer. J Urol, 182, 721-7. https://doi.org/10.1016/j.juro.2009.03.081
  16. Kim J.P, Lee JH, Kim SJ, et al (2005). Clinicopathologic characteristics and prognostic factors in 10783 patients with gastric cancer. Gastric Cancer, 1, 125-33.
  17. Kamesaki. H (1998). Mechanisms involved in chemotherapyinduced apoptosis and their implications in cancer chemotherapy. Inter J Hematol, 68, 29-43. https://doi.org/10.1016/S0925-5710(98)00038-3
  18. Keshgegian AA, Johnston E, Cnaan A (1998). Bcl-2 oncoprotein positivity and high MIB- 1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol, 110, 443-9. https://doi.org/10.1093/ajcp/110.4.443
  19. Karasek M, et al (2002). Expression of melatonin MT(1) and MT(2) receptors, and ROR alpha(1) receptor in transplantable murine Colon 38 cancer. Neuro Endocrinol Lett, 1, 55-60.
  20. Lehnerdt G.F, Franz P, Bankfalvi A, et al (2009). The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. Ann Oncol, 20, 1094-99. https://doi.org/10.1093/annonc/mdn763
  21. Milne A.N, Carneiro F, Morain C, et al (2009). Nature meets nurture: molecular genetics of gastric cancer. Human Genetics, 126, 615-28. https://doi.org/10.1007/s00439-009-0722-x
  22. Martinou J.C, Youle RJ (2011). Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Developmental Cell, 21, 92-101. https://doi.org/10.1016/j.devcel.2011.06.017
  23. Moul JW (2012). Angiogenesis, p53, Bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol, 35, 399-407.
  24. MowlaS, Emadi Bayegi M, Ziaee SA (2005). Evaluating expression and potential diagnostic and prognostic values of Survivin in bladder tumors a preliminary report. Printed in IRAN, 2, 141-7.
  25. Mistry,T (2008). Leptin and adiponectin interact in the regulation of prostate cancer cell growth via modulation of p53 and bcl 2 expression. BJU international, 1317-22.
  26. Ofner D, Riehemann K, Maier H, ssssss (1995). Immunohistochemically detectable Bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer, 72, 981-985. https://doi.org/10.1038/bjc.1995.446
  27. Parkin, D, Bray F, Ferlay J, et al (2002). Global cancer statistics. CA Cancer J, 55, 74-108.
  28. Parkin DM, Bray FI, Devesa SS, et al (2001). Cancer burden in the year 2000. The global picture. European Journal of Cancer, 37 ,4-66.
  29. Pinto E, Roviello F, Stefano A.D (1994). Early gastric cancer: report on 142 patients observed over 13 years. Jpn J Clin Oncol, 24, 12-19.
  30. Rostamizadeh L, Fakhrjou A, Montazeri V, et al (2013). Bcl-2 Gene expression in human breast cancers in Iran. Asian Pac J Cancer Prev, 14, 4209-14. https://doi.org/10.7314/APJCP.2013.14.7.4209
  31. Sung, N, Choi KS, Park EC, et al. (2007). Smoking, alcohol and gastric cancer risk in Korean men: the National Health Insurance Corporation Study. Br J Cancer, 97, 700-4. https://doi.org/10.1038/sj.bjc.6603893
  32. Seto M, Jaeger U, Hockett RD, et al. (1988). Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J, 7, 123-31.
  33. Sadjadi A, Nouraie M, Ghorbani A, et al (2009). Epidemiology of breast cancer in the Islamic republic of Iran: first results from a population-based cancer registry. East Mediterr Health J, 15, 1426-31.
  34. Sulkowska M, Famulski W, Sulkowski S, et al (2003). Correlation between Bcl-2 protein expression and some clinicopathological features of oral squamous cell carcinoma. Pol J Pathol, 54, 49-52.
  35. Silvestrini R, Benini E, Veneroni S, et al (1996). p53 and Bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol, 14, 1604-10.
  36. Stackhouse GB, Sesterhenn IA, Bauer JJ, et al (1999). p53 and Bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol, 162, 2040-5. https://doi.org/10.1016/S0022-5347(05)68095-0
  37. WHO,(2004) Initiative for vaccine research team of the department of immunization, vaccines and biologicals. epidemiology of helicobacter pylori and gastric cancer. in proceedings of the fourth global vaccine research forum.
  38. Young RL, Korsmeyer SJ (1993). A negative regulatory element in the Bcl-2 5’- untranslated region inhibits expression from an upstream promoter. Mol Cell Biol, 13(6) ,3686-3697. https://doi.org/10.1128/MCB.13.6.3686
  39. Yan JJ, Chen FF, Tsai YC, et al (2009). Immunohistochemical detection of Bcl-2 protein in small cell carcinomas. Oncology, 53, 6-11.
  40. Zhang GJ, Kimijima I, Tsuchiya A et al (1998). The role of Bcl-2 expression in breast carcinomas [review]. Oncol Rep, 5, 1211-6.
  41. Zinkel S, Gross A, Yang E (2006). BCL2 family in DNA damage and cell cycle control. Cell Death Differ, 13, 1351-9. https://doi.org/10.1038/sj.cdd.4401987
  42. Zhang GJ, Kimijima I, Tsuchiya A, et al (1998). The role of Bcl-2 expression in breast carcinomas (Review). Oncol Rep, 5, 1211-16.